A randomized phase II trial of erlotinib vs. S-1 as a third- or fourth-line therapy for patients with wild-type EGFR non-small cell lung cancer (HOT1002)
Sign Up to like & getrecommendations! Published in 2017 at "Cancer Chemotherapy and Pharmacology"
DOI: 10.1007/s00280-017-3432-4
Abstract: PurposeA high proportion of patients with wild-type EGFR non-small cell lung cancer (NSCLC) receive third-line therapy and beyond, with no prospective randomized trials addressing the issue. This study aimed to select the most suitable regimen… read more here.
Keywords: type egfr; wild type; line therapy;
Cyclic trans-phosphorylation in a homodimer as the predominant mechanism of EGFRvIII action and regulation
Sign Up to like & getrecommendations! Published in 2018 at "Oncotarget"
DOI: 10.18632/oncotarget.24058
Abstract: Despite intensive research no therapies targeted against the oncogenic EGFRvIII are present in the clinic. One of the reasons is the elusive nature of the molecular structure and activity of the truncated receptor. The recent… read more here.
Keywords: trans phosphorylation; type egfr; mutant receptor; receptor ... See more keywords
Shikonin sensitizes wild-type EGFR NSCLC cells to erlotinib and gefitinib therapy
Sign Up to like & getrecommendations! Published in 2018 at "Molecular Medicine Reports"
DOI: 10.3892/mmr.2018.9347
Abstract: As patients with non-small cell lung cancer (NSCLC) and wild-type epidermal growth factor receptor (EGFR) are resistant to treatment with erlotinib or gefitinib, potential chemosensitizers are required to potentiate wild-type EGFR NSCLC cells to erlotinib/gefitinib… read more here.
Keywords: type egfr; erlotinib gefitinib; egfr nsclc; wild type ... See more keywords